| Website | avedro.com |
| @Avedro_Inc | |
| Category | BioTech |
| Phone | 781-768-3400 |
| Employees | |
| Founded | 2007 |
| TOTAL | $87.8M |
| FUNDING TOTAL | $87.8M |
| Venture Round, 1/11 | $6.3M |
| Venture Round, 5/11 | $13M |
| Series C, 7/11 SCP Vitalife Partners Aperture Venture Partners | $25M |
| Venture Round, 2/12 SCP Vitalife Partners M. Carl Johnson III | $500k |
| Series D, 3/13 Third Point Ventures Prism VentureWorks De Novo Ventures Flagship Ventures Aperture Venture Partners SCP Vitalife Partners Borealis Ventures Echelon Ventures | $43M |
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.
